Key Highlights

  • argenx shares rallied 16% to end at $987.84.
  • The Phase 3 ALKIVIA trial of Vyvgart Hytrulo for autoimmune myositis reached its primary endpoint.
  • The pooled IMNM/DM group showed a statistically significant 15.4-point TIS improvement versus placebo over 52 weeks.
  • The IMNM subset showed notable efficacy, while the DM-only subgroup showed clinically relevant but not statistically significant data.

argenx SE (NASDAQ: ARGX) shares rallied 16% to end at $987.84 after the company reported that its Phase 3 ALKIVIA trial of Vyvgart Hytrulo for autoimmune myositis reached its primary endpoint, highlighting a statistically significant 15.4-point TIS improvement in the pooled IMNM/DM group versus placebo over 52 weeks.

What Happened

Although the DM-only subgroup yielded clinically relevant data without statistical significance, the IMNM subset exhibited notable efficacy, with the overall safety profile remaining consistent with prior efgartigimod clinical studies.

Market Reaction

Shares rallied sharply as investors responded to the trial's success on its primary endpoint and the consistency of the safety profile with prior efgartigimod research, even as the split results between the IMNM and DM subgroups added some nuance to the overall data set.

Outlook

The split results between the IMNM and DM subgroups are likely to be a key focus for regulators and investors as argenx determines its regulatory strategy for Vyvgart Hytrulo in autoimmune myositis.